Abstract
Cystinosis is an autosomal recessive disorder, caused by mutations in the lysosomal cystine carrier cystinosin, encoded by the CTNS gene. The disease generally manifests with Fanconi syndrome during the first year of life and progresses towards end stage renal disease before the age of 10 years. Cysteamine depletes intralysosomal cystine content, postpones the deterioration of renal function and the occurrence of extra-renal organ damage. Based on the pharmacokinetic data, patients with cystinosis are advised to use cysteamine every 6 h. The aim of this study was (1) to evaluate the cysteamine dose regimen in Dutch patients with cystinosis and (2) to determine morning polymorphonuclear (PMN) leukocyte cystine content 6 h vs 9 h after the last evening cysteamine dose. Only 5/22 of Dutch cystinosis patients ingested cysteamine every 6 h. Morning (8 a.m.) PMN cystine content in 11 examined patients was elevated 9 h after 12.5–15 mg/kg evening cysteamine dose compared to the value 6 h after the ingestion of the same dose (0.73±0.81 nmol vs 0.44±0.52 nmol cystine/mg protein, p =0.02). In conclusion, only the minority of Dutch cystinosis patients follows the recommended strict cysteamine dose regimen. We provide evidence that cysteamine has to be administered every 6 h, including the night, as it has much better effect for maintaining low PMN cystine levels.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kalatzis V, Cherqui S, Antignac C, Gasnier B (2001) Cystinosin, the protein defective in cystinosis, is a H+-driven lysosomal cystine transporter: EMBO J 20:5940–5949
Town M, Jean G, Cherqui S, Attard M, Forestier L, Whitmore SA, Callen DF, Gribouval O, Broyer M, Bates GP, van’t Hoff W, Antignac C (1998) A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. Nat Genet 18:319–324
Gahl W, Thoene JG, Schneider J (2001) Cystinosis: a disorder of lysosomal membrane transport. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 5085–6108
Gahl WA, Thoene JG, Schneider JA (2002) Cystinosis. N Engl J Med 347:111–121
Thoene JG, Oshima RG, Crawhall JC, Olson D, Schneider JA (1976) Cystinosis. Intracellular cystine depletion by aminothiols in vitro and in vivo. J Clin Invest 58:180–189
Pisoni RL, Thoene JG, Christensen HN (1985) Detection and characterization of carrier-mediated cationic amino acid transport in lysosomes of normal and cystinotic human fibroblasts: role of therapeutic cystine removal. J Biol Chem 260:4791–4798
Kleta R, Kaskel F, Dohil R, Goodyer P, Guay-Woodford LM, Harms E, Ingelfinger JR, Koch VH, Langman G, Leonard MB, Mannon RB, Sarwal M, Schneider JA, Skovby JG, Sonies BC, Thoene JG, Trauner D, Gahl WA (2005) First NIH/Office of Rare Diseases Conference on Cystinosis: past, present, and future. Pediatr Nephrol 20:452–454
Markello TC, Bernardini IM, Gahl WA (1993) Improved renal function in children with cystinosis treated with cysteamine. N Engl J Med 328:1157–1162
Sonies BC, Almajid P, Kleta R, Bernardini I, Gahl WA (2005) Swallowing dysfunction in 101 patients with nephropathic cystinosis: benefit of long-term cysteamine therapy. Medicine (Baltimore) 84:137–146
Smolin LA, Clark KF, Thoene JG, Gahl WA, Schneider JA (1988) A comparison of the effectiveness of cysteamine and phosphocysteamine in elevating plasma cysteamine concentration and decreasing leukocyte free cystine content in nephropathic cystinosis. Pediatr Res 23:616–620
Belldina EB, Huang MY, Schneider JA, Brundage RC, Tracy TS (2003) Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients. Br J Clin Pharmacol 56:520–525
Smolin LA, Clark KF, Schneider JA (1987) An improved method for heterozygote detection of cystinosis, using polymorphonuclear leukocytes. Am J Hum Genet 41:266–275
Levtchenko E, de Graaf-Hess A, Wilmer M, van den Heuvel L, Monnens L, Blom H (2004) Comparison of cystine determination in mixed leukocytes vs polymorphonuclear leukocytes for diagnosis of cystinosis and monitoring of cysteamine therapy. Clin Chem 50:1686–1688
De Graaf A, Trijbels F, Blom H (1999) New method for determining cystine in leukocytes and fibroblasts. Clin Chem 45:2224–2228
Schneider JA (2004) Treatment of cystinosis: simple in principle, difficult in practice. J Pediatr 145:436–438
Kleta R, Bernardini I, Ueda M, Varade WS, Phornphutkul C, Krasnewich D, Gahl WA (2004) Long follow-up of well treated nephropathic cystinosis patients. J Pediatr 145:555–560
Dohil R, Newbury R, Sellers Z, Deutsch R, Schneider JA (2003) The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine. J Pediatr 143:224–230
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Levtchenko, E.N., van Dael, C.M., de Graaf-Hess, A.C. et al. Strict cysteamine dose regimen is required to prevent nocturnal cystine accumulation in cystinosis. Pediatr Nephrol 21, 110–113 (2006). https://doi.org/10.1007/s00467-005-2052-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-005-2052-0